Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathon B Cohen

Showing results (121-130 of 129) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 129 results.
Lancet (London, England)|March 7, 2021
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R Mato, Nirav N Shah, Wojciech Jurczak, et al.
American Journal of Hematology|January 13, 2024
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomesJames R Cerhan, Matthew J Maurer, Brian K Link, et al.
Blood Advances|October 24, 2023
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphomaJames N Gerson, Elizabeth Handorf, Diego Villa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2025
FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular LymphomaMatthew J Maurer, Vit K Prochazka, Tarec Christoffer El-Galaly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2019
Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab EraJames N Gerson, Elizabeth Handorf, Diego Villa, et al.
Blood Advances|December 11, 2025
Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell LymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Blood Cancer Journal|April 25, 2026
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapyYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Blood Advances|February 24, 2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Leukemia|March 4, 2021
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphomaReid W Merryman, Luca Castagna, Laura Giordano, et al.
Pageof 13

Showing results (121-130 of 129) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 129 results.
Lancet (London, England)|March 7, 2021
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R Mato, Nirav N Shah, Wojciech Jurczak, et al.
American Journal of Hematology|January 13, 2024
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomesJames R Cerhan, Matthew J Maurer, Brian K Link, et al.
Blood Advances|October 24, 2023
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphomaJames N Gerson, Elizabeth Handorf, Diego Villa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2025
FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular LymphomaMatthew J Maurer, Vit K Prochazka, Tarec Christoffer El-Galaly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2019
Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab EraJames N Gerson, Elizabeth Handorf, Diego Villa, et al.
Blood Advances|December 11, 2025
Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell LymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Blood Cancer Journal|April 25, 2026
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapyYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Blood Advances|February 24, 2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Leukemia|March 4, 2021
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphomaReid W Merryman, Luca Castagna, Laura Giordano, et al.
Pageof 13